Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
127 results about "Hepcidin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hepcidin is a protein that in humans is encoded by the HAMP gene. Hepcidin is a key regulator of the entry of iron into the circulation in mammals. During conditions in which the hepcidin level is abnormally high, such as inflammation, serum iron falls due to iron trapping within macrophages and liver cells and decreased gut iron absorption. This typically leads to anemia due to an inadequate amount of serum iron being available for developing red blood cells. When the hepcidin level is abnormally low such as in hemochromatosis, iron overload occurs due to increased ferroportin mediated iron efflux from storage and increased gut iron absorption.
Measurement of bioactive hepcidins
ActiveUS20060019339A1Enhancing innate immunityAntibacterial agentsBiocideMicroorganismVertebrate Animals
The present invention concerns a method for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal; a method for measuring the level of hepcidin gene expression in a vertebrate animal; and a method for regulating the production of native, bioactive hepcidin in a vertebrate animal in vivo. The present invention also concerns an antibody or fragment thereof that specifically binds to a continuous, discontinuous, and / or conformational epitope of a mature and bioactive hepcidin folded as in the native configuration; and a pharmaceutical composition that includes the antibody or a hepcidin polypeptide and that provides antimicrobial, agonistic, or antagonistic activities in vivo in a vertebrate animal.
Owner:INTRINSIC LIFESCIENCES LLC
Biomarker for ovarian and endometrial cancer: hepcidin
ActiveUS7510842B2Improve diagnostic capabilitiesImprove the level ofBiocideCompound screeningThyroxine measurementMass spectrometry
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +2
Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
ActiveUS20070224186A1Modulate bindingUseful in treatmentPeptide/protein ingredientsAntipyreticAssayMonoclonal antibody
The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and / or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and / or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin / mature hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.
Owner:DRG INTERNATIONAL INC
Preparation method of zebrafish with hepcidin gene knocked out by use of CRISPR / Cas9 technology
The present invention mainly relates to formation of zebrafish with hepcidin gene knocked out, by the use of CRISPR / Cas9 technology, a unique PAM region is designed, so that the hepcidin gene in the zebrafish is knocked out, and other genes are not accidentally injured. The first case of hepcidin knockout transgenic animal model zebrafish has great significance, the hepcidin is a major factor in the regulation of iron, once the hepcidin is knocked out, an animal model can be successfully molded into an iron overload animal model, the human factor intervention can be excluded, the hepcidin has great significance to iron expression researches, meanwhile compared with the traditional gene knockout technology, the CRISPR / Cas9 technology has low toxicity, high accuracy, high efficiency, short success cycle and other characteristics, and the hepcidin gene can be faster knocked out.
Owner:徐又佳
Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
Owner:DRG INTERNATIONAL INC
Mini-hepcidin peptides and methods of using thereof
Owner:RGT UNIV OF CALIFORNIA
Biomarker for ovarian and endometrial cancer: hepcidin
ActiveUS20070054329A1Improve diagnostic capabilitiesImprove the level ofBiocideCompound screeningMass spectrometryOncology
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +2
Biomaker for ovarian and endometrial cancer: hepcidin
InactiveUS20100068724A1Improve diagnostic capabilitiesImprove the level ofCompound screeningBiocideThyroxine measurementMass spectrometry
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
Owner:VERMILLION INC +2
Biomarkers and methods for diagnosing, predicting and/or prognosing sepsis and uses thereof
InactiveUS20100292131A1Peptide librariesPeptide/protein ingredientsHealthy subjectsBiomarker (petroleum)
The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject or for the differentiation between sepsis and SIRS in a subject, the method comprising(a) measuring the level of pro-hepcidin (pro-HEPC) in a biological sample taken from said subject, (b) measuring the level of at least one further biomarker selected from the group consisting of soluble TNF-receptor 2 (sTNFR2), Pentraxin-3 (PTX-3), Macrophage Colony-Stimulating Factor (MCSF), pro-Brain Natriuretic Protein (pro-BNP), one or more members of the Histone protein family, Procalcitonin (PCT) and c-Reactive Protein (CRP) in a biological sample from said subject, (c) using said measurements obtained in steps (a) and (b) to create a profile for said biomarkers and (d) comparing said profile with a reference biomarker profile obtained form a patient having SIRS or from a healthy subject.
Owner:BIOCARTIS NV
Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
InactiveUS8999935B2Treating preventing reducing riskPrevent and reduce riskOrganic active ingredientsHormone peptidesDysostosisPost menopausal
Owner:NEW YORK UNIV
Modified Mini-Hepcidin Peptides and Methods of Using Thereof
Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.
Owner:RGT UNIV OF CALIFORNIA
Hepcidin and mini-hepcidin analogues and uses thereof
The present invention provides novel hepcidin analogues, and related methods of using these hepcidin analogues to treat or prevent a variety of diseases and disorders, including iron overload diseases such as hereditary hemochromatosis, iron-loading anemias, and other conditions and disorders described herein.
Owner:PROTAGONIST THERAPEUTICS INC
Hepcidin analogues and uses thereof
ActiveUS20160222076A1Hormone peptidesPeptide/protein ingredientsIron loading anemiaIron Overload Disease
The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and / or prevention of a variety of diseases, conditions or disorders, including treatment and / or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
Owner:PROTAGONIST THERAPEUTICS INC
Hepcidin analogues and uses thereof
ActiveUS9822157B2Hormone peptidesPeptide/protein ingredientsIron loading anemiaIron Overload Disease
Owner:PROTAGONIST THERAPEUTICS INC
Large yellow croaker hepcidin antibacterial peptide and preparation method thereof
ActiveCN101974082AHigh molecular weightOptimizing Denaturation and Refolding ConditionsPeptide preparation methodsFermentationProkaryotic expressionGene engineering
The invention discloses a large yellow croaker hepcidin antibacterial peptide and a preparation method thereof, relating to fish gene engineering in the biotechnology field, and providing a large yellow croaker hepcidin antibacterial peptide and a preparation method thereof. The preparation method of the large yellow croaker hepcidin antibacterial peptide comprises the following steps: cloning a large yellow croaker hepcidin antibacterial peptide gene; constructing a recombinant vector; converting a host cell; selecting positive clone for prokaryotic expression; separating and purifying an expression product; and obtaining the large yellow croaker hepcidin antibacterial peptide. During separation and purification, the yield of protein is improved, thus solving the problem of protein precipitation when the hepcidin antibacterial peptide expresses renaturation. The solution has simple preparation and low cost. The prepared large yellow croaker hepcidin antibacterial peptide has high broad-spectrum antimicrobial activity, can be used for scientific researches, can serve as feed additive for preventing and curing diseases of sea farming fishes and has wide application prospect.
Owner:XIAMEN UNIV
Mini-Hepcidin Peptides and Methods of Using thereof
Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.
Owner:RGT UNIV OF CALIFORNIA
Method of detecting and/or measuring hepcidin in a sample
InactiveUS20090173876A1Convenient treatmentParticle separator tubesIsotope separationMass Spectrometry-Mass SpectrometryBiochemistry
Owner:AMGEN INC
SiRNA and recombination lentivirus from preventing hepcidin from regulating protein and uses thereof
The invention discloses an RNA with little interference for inhibiting the expression of an iron regulating element regulatory protein (HJV). The RNA with little interference is in reverse complementation with the iron regulating element regulatory protein gene mRNA, and the length of the RNA is 19-27bp. The invention further discloses a DNA for coding the corresponding shRNA of the RNA with little interference and a recombined slow virus capable of expressing the shRNA. The RNA with little interference, the DNA capable of coding the shRNA and the recombined slow virus can effectively inhibit the expression of the iron regulating element regulatory protein in vivo, improve the level of the iron regulating element and reduce the level of serum iron in vivo, thereby reaching the aim of curing diseases related to iron metabolism.
Owner:THE HONG KONG POLYTECHNIC UNIV SHENZHEN RES INST
Differential diagnosis with hepcidin
The present invention concerns the use of hepcidin as a marker for detecting inflammatory chronic diseases and especially for a differential diagnosis to detect inflammatory chronic diseases and / or non-inflammatory chronic diseases. The present invention also concerns a method for detecting inflammatory chronic diseases, non-inflammatory chronic diseases and / or acute phase reactions comprising the determination of hepcidin.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Expression product in series of two fish antibacterial peptide genes and expression method thereof
ActiveCN101906165AGood antibacterial effectHigh antibacterial activityPeptide preparation methodsHybrid peptidesStaphylococcus aureusCancer research
The invention discloses an expression product in series of two fish antibacterial peptide genes and an expression method thereof, relating to the gene engineering technology of marine organism, providing an expression product in series of the two fish antibacterial peptide genes and construction of an expression vector in series of two fish Hepcidin and a preparation method for the expression product in series. In the invention, two fish hepcidin genes are expressed in series by a pET32a prokaryocyte expression vector to realize the soluble expression of two antibacterial peptide hepcidin at the same time; the expression level of two antibacterial peptides in series is over 50mg / L, the soluble expression product in series is purified by a N-terminal His-Tag affinity chromatography, and then cuts off a protein label in series by enterokinase; and the cut mixture is purified by a Ni affinity chromatographic column to obtain a purified Hepcidin expression product in series. The purified expression product has obvious inhibiting effect on Staphylococcus aureus, Aeromonas hydrophila, micrococcus lysodeikticus and the like.
Owner:XIAMEN UNIV
Analogues of hepcidin mimetics with improved in vivo half lives
InactiveUS20190002503A1High molecular weightImprove solubilityHormone peptidesPeptide/protein ingredientsHalf-lifeMedicine
Owner:PROTAGONIST THERAPEUTICS INC
Diagnostic method for disease by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or down-regulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
Owner:DRG INTERNATIONAL INC
Il-22-fc and hepcidin activity
InactiveUS20130121959A1Increasing hepcidin expressionHigh activityAntibody mimetics/scaffoldsAntibody ingredientsMedicineHepcidin
Owner:AMGEN INC
Expression carrier for black porgy antibiotic peptide Hepcidin and expression product and constructing preparation method
The invention discloses an expressing carrier of black porgy antibiotic peptide Hepcidin, expressing product and preparing method, which is characterized by the following: incorporating E. coliTrc promoter, protein project improving CKS gene and procaryotic expressing carrier pTrc-CKS of histidine tag (His-Tag); connecting to black porgy Hepcidin gene; constructing pTrc-CKS / hepcidin expressing plasmid; possessing P3C enzyme cutting site; fusing six histidine on C end; getting CKS-hepcidin; purifying through C end His-Tag affinity chromatography; getting the purified product; cutting CKS with P3C enzyme in fuse protein; getting the purified Hepcidin.
Owner:XIAMEN UNIV
Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
Owner:DRG INTERNATIONAL INC
Methods for measuring levels of bioactive human hepcidin
Owner:INTRINSIC LIFESCIENCES LLC
Antibiotic peptide gene and its yeast expression carrier
A scophthalmus maximus peptide hepcidin gene and its yeast expression vector, the method is to separate and clone Scophthalmus maximus peptide cDNA and ití»s gene groupí»s gene, regroup this geneí»s mature peptides to yeast cell expression vector®ñpGAPZB, then to form confluent expression vector®ñpGAPZB-the6his, and conversion Pichia pastoris strain SMD1168ú¼and get the yeast plant that can express mature peptide albumen steadily, this peptide gene can be considered to finish expression by passing the SDS-PAGE and Western blot test. This invention clone Scophthalmus maximums peptide gene and form mature yeast expression vector in the cell at the first time, it can be used as fish and other aquatic animalí»s feed additive by yeast form directly, and it doní»t request to separate and purificate the regroup peptideíúThe invention also can be used to clone many fishí»s peptidegene and its expression vector, and used to prevention and cure fish and other aquatic animalí»s disease.
Owner:YELLOW SEA FISHERIES RES INST CHINESE ACAD OF FISHERIES SCI
Treatment of osteoporosis in peri- and post- menopausal women with hepcidin
InactiveUS20100204122A1Treating preventing reducing riskInhibit bone formationOrganic active ingredientsPeptide/protein ingredientsPost menopausalDuring menopause
The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.
Owner:NEW YORK UNIV
Markers for acute kidney injury
Provided are methods and compositions for predicting the development of kidney disease, including acute kidney injury. In certain aspects and embodiments the provided methods and compositions are particularly useful for predicting kidney injury following an event likely to cause kidney injury and / or kidney failure in a patient, such as a cardiac surgery, e.g., a surgery involving a cardiopulmonary bypass (CPB), such as a coronary artery bypass graft surgery. In some embodiments, the higher the urinary hepcidin-to-urinary creatinine ratio (uHep / uCr) at 6-24 hours following initiation of CPB, the lower is the risk for development of AKI determined by RIFLE criteria in the ensuing four to five days. Conversely, the higher the urinary NGAL to urinary creatinine ratio (uNGAL / uCr) at 6-24 hours following initiation of CPB, the higher is the risk of developing CPB-mediated AKI over the same time period.
Owner:INTRINSIC LIFESCIENCES LLC +1
Recombinant human iron-regulatory hormone adenovirus, preparation method and application thereof
InactiveCN101358201ASimple processHigh titerGenetic material ingredientsGenetic engineeringHormones regulationVirus
The present invention discloses a recombinant human hepcidin adenovirus (Ad-hepc), which contains human hepcidin gene and adenovirus vector. The present invention also discloses a preparation of the recombinant human hepcidin adenovirus and an application thereof. The present invention utilizes defective adenovirus to deliver the human hepcidin gene into the tissue cells of the body, so that the virus can express hepcidin protein in the body of a patient.
Owner:THE HONG KONG POLYTECHNIC UNIV SHENZHEN RES INST
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com